ducovest

BIB:NSD-ProShares Ultra Nasdaq Biotechnology (USD)

ETF | Trading--Leveraged Equity | NASDAQ Global Market

Last Closing

USD 52.19

Change

0.00 (0.00)%

Market Cap

USD 0.44B

Volume

8.63K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The investment seeks daily investment results that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index?. The fund invests in securities and derivatives that ProShare Advisors believes, in combination, should have similar daily return characteristics as two times (2x) the daily return of the index. The index is a modified capitalization weighted index that includes securities of NASDAQ listed companies that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark ("ICB") which also meet other eligibility criteria determined by NASDAQ. The fund is non-diversified.

Company Website : www.proshares.com

Currency: USD

Country : USA

Inception Date: 06/04/2010

Primary Benchmark: NASDAQ Biotechnology TR USD

Primary Index: S&P 500 TR USD

Gross Expense Ratio: 1.04%

Management Expense Ratio: 0.95 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Holdings

N/A

Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-25 )

Largest Industry Peers for Trading--Leveraged Equity

Symbol Name Mer Price(Change) Market Cap
TQQQ ProShares UltraPro QQQ 0.95 %

-0.19 (-0.21%)

 USD 27.82B

ETFs Containing BIB

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Leveraged Equity) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -8.52% 50% F 41% F
Dividend Return 0.80% 50% F 15% F
Total Return -7.72% 50% F 40% F
Trailing 12 Months  
Capital Gain -10.31% 50% F 39% F
Dividend Return 0.79% 50% F 14% F
Total Return -9.52% 50% F 39% F
Trailing 5 Years  
Capital Gain -16.64% 50% F 41% F
Dividend Return 0.82% 50% F 3% F
Total Return -15.82% 50% F 37% F
Average Annual (5 Year Horizon)  
Capital Gain -0.42% 50% F 37% F
Dividend Return -0.33% 50% F 33% F
Total Return 0.10% 50% F 5% F
Risk Return Profile  
Volatility (Standard Deviation) 37.54% 100% F 51% F
Risk Adjusted Return -0.87% 50% F 33% F
Market Capitalization 0.44B 50% F 34% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.